Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,431
archived clinical trials in
Anemia

Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)
A Multi-center, Randomized, Active Controlled Study to Investigate the Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)
Status: Enrolling
Updated:  1/22/2018
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)
A Multi-center, Randomized, Active Controlled Study to Investigate the Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)
Status: Enrolling
Updated: 1/22/2018
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
Click here to add this to my saved trials
Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in Subjects Who Display Postpartum Anemia
Comparison of the Safety and Efficacy of Intravenous Iron vs Oral Iron in Subjects Who Display Postpartum Anemia
Status: Enrolling
Updated:  1/22/2018
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in Subjects Who Display Postpartum Anemia
Comparison of the Safety and Efficacy of Intravenous Iron vs Oral Iron in Subjects Who Display Postpartum Anemia
Status: Enrolling
Updated: 1/22/2018
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
Click here to add this to my saved trials
Comparison of Safety and Efficacy of Intravenous Iron Versus Oral Iron in Chronic Renal Failure Subjects With Anemia
Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in Chronic Renal Failure Subjects With Anemia
Status: Enrolling
Updated:  1/22/2018
Luitpold Pharmaceuticals
mi
from
Valley Forge, PA
Comparison of Safety and Efficacy of Intravenous Iron Versus Oral Iron in Chronic Renal Failure Subjects With Anemia
Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in Chronic Renal Failure Subjects With Anemia
Status: Enrolling
Updated: 1/22/2018
Luitpold Pharmaceuticals
mi
from
Valley Forge, PA
Click here to add this to my saved trials
Safety and Efficacy of Iron Sucrose in Children
Comparison of the Safety and Efficacy of Three Iron Sucrose Maintenance Regimens in Pediatric Chronic Kidney Disease (CKD) Patients
Status: Enrolling
Updated:  1/22/2018
Luitpold Pharmaceutials
mi
from
Norristown, PA
Safety and Efficacy of Iron Sucrose in Children
Comparison of the Safety and Efficacy of Three Iron Sucrose Maintenance Regimens in Pediatric Chronic Kidney Disease (CKD) Patients
Status: Enrolling
Updated: 1/22/2018
Luitpold Pharmaceutials
mi
from
Norristown, PA
Click here to add this to my saved trials
Long Term Safety Study of (VIT45) Extension Study: Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
Open Label Extension Study Evaluating the Long Term Safety, Tolerability and Efficacy of an Iron Maintenance Dosing Strategy Utilizing Intravenous VIT45 in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
Status: Enrolling
Updated:  1/22/2018
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
Long Term Safety Study of (VIT45) Extension Study: Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
Open Label Extension Study Evaluating the Long Term Safety, Tolerability and Efficacy of an Iron Maintenance Dosing Strategy Utilizing Intravenous VIT45 in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
Status: Enrolling
Updated: 1/22/2018
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
Click here to add this to my saved trials
VIT45 Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
Comparison of Safety & Efficacy of a Unique Intravenous Iron (VIT45) Preparation vs Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
Status: Enrolling
Updated:  1/22/2018
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
VIT45 Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
Comparison of Safety & Efficacy of a Unique Intravenous Iron (VIT45) Preparation vs Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
Status: Enrolling
Updated: 1/22/2018
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
Click here to add this to my saved trials
Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in the Treatment of Anemia Secondary to Heavy Uterine Bleeding
Comparison of the Safety and Efficacy of Intravenous Iron vs Oral Iron in the Treatment of Anemia Secondary to Heavy Uterine Bleeding
Status: Enrolling
Updated:  1/22/2018
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in the Treatment of Anemia Secondary to Heavy Uterine Bleeding
Comparison of the Safety and Efficacy of Intravenous Iron vs Oral Iron in the Treatment of Anemia Secondary to Heavy Uterine Bleeding
Status: Enrolling
Updated: 1/22/2018
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
Click here to add this to my saved trials
Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients
A Multi-center, Randomized Controlled Study to Investigate the Safety and Tolerability of IV Ferric Carboxymaltose (FCM) vs Standard Medical Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients
Status: Enrolling
Updated:  1/22/2018
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients
A Multi-center, Randomized Controlled Study to Investigate the Safety and Tolerability of IV Ferric Carboxymaltose (FCM) vs Standard Medical Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients
Status: Enrolling
Updated: 1/22/2018
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
Click here to add this to my saved trials
Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Standard of Care in Treating Iron Deficiency Anemia
A Multi-center, Randomized, Controlled Study to Investigate the Safety and Tolerability of Intravenous Ferric Carboxymaltose (FCM) vs. Standard Medical Care in Treating Iron Deficiency Anemia
Status: Enrolling
Updated:  1/22/2018
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Standard of Care in Treating Iron Deficiency Anemia
A Multi-center, Randomized, Controlled Study to Investigate the Safety and Tolerability of Intravenous Ferric Carboxymaltose (FCM) vs. Standard Medical Care in Treating Iron Deficiency Anemia
Status: Enrolling
Updated: 1/22/2018
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
Click here to add this to my saved trials
Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Iron Dextran in Treating Iron Deficiency Anemia
A Multi-Center, Randomized, Controlled Study to Investigate the Safety and Tolerability of Intravenous Ferric Carboxymaltose (FCM) vs. Iron Dextran in Treating Iron Deficiency Anemia
Status: Enrolling
Updated:  1/22/2018
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Iron Dextran in Treating Iron Deficiency Anemia
A Multi-Center, Randomized, Controlled Study to Investigate the Safety and Tolerability of Intravenous Ferric Carboxymaltose (FCM) vs. Iron Dextran in Treating Iron Deficiency Anemia
Status: Enrolling
Updated: 1/22/2018
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
Click here to add this to my saved trials
Safety and Tolerability of a Single Dose of FCM vs. Standard of Care in Treating Iron Deficiency Anemia
A Multi-Center, Randomized, Controlled Study to Investigate the Safety and Tolerability of a Single Dose of Intravenous Ferric Carboxymaltose (FCM) vs. Standard Medical Care in Treating Iron Deficiency Anemia in Subjects Who Are Not Dialysis Dependent
Status: Enrolling
Updated:  1/22/2018
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
Safety and Tolerability of a Single Dose of FCM vs. Standard of Care in Treating Iron Deficiency Anemia
A Multi-Center, Randomized, Controlled Study to Investigate the Safety and Tolerability of a Single Dose of Intravenous Ferric Carboxymaltose (FCM) vs. Standard Medical Care in Treating Iron Deficiency Anemia in Subjects Who Are Not Dialysis Dependent
Status: Enrolling
Updated: 1/22/2018
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
Click here to add this to my saved trials
Iron Sucrose in Non-Dialysis Dependent (NDD-CKD) Pediatric Patients
Single-Dose Pharmacokinetics of Venofer (Iron Sucrose Injection) in Non-Dialysis Dependent (NDD-CKD) Pediatric Patients Receiving or Not Receiving Erythropoiesis Stimulating Agents (ESA's)
Status: Enrolling
Updated:  1/22/2018
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
Iron Sucrose in Non-Dialysis Dependent (NDD-CKD) Pediatric Patients
Single-Dose Pharmacokinetics of Venofer (Iron Sucrose Injection) in Non-Dialysis Dependent (NDD-CKD) Pediatric Patients Receiving or Not Receiving Erythropoiesis Stimulating Agents (ESA's)
Status: Enrolling
Updated: 1/22/2018
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
Click here to add this to my saved trials
Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function
Randomized Evaluation of Efficacy and Safety of Ferric Carboxymaltose in Patients With Iron Deficiency Anemia and Impaired Renal Function
Status: Enrolling
Updated:  1/22/2018
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function
Randomized Evaluation of Efficacy and Safety of Ferric Carboxymaltose in Patients With Iron Deficiency Anemia and Impaired Renal Function
Status: Enrolling
Updated: 1/22/2018
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
Click here to add this to my saved trials
Choosing Opioid Management for Pain and Analyzing Acute Chest Syndrome (ACS) Rates Equally
Choosing Opioid Management for Pain and Analyzing ACS Rates Equally
Status: Enrolling
Updated:  1/23/2018
Children's Healthcare of Atlanta
mi
from
Atlanta, GA
Choosing Opioid Management for Pain and Analyzing Acute Chest Syndrome (ACS) Rates Equally
Choosing Opioid Management for Pain and Analyzing ACS Rates Equally
Status: Enrolling
Updated: 1/23/2018
Children's Healthcare of Atlanta
mi
from
Atlanta, GA
Click here to add this to my saved trials
Pilot and Feasibility Trial of Plerixafor for Hematopoietic Stem Cell (HSC) Mobilization in Patients With Sickle Cell Disease Pilot and Feasibility Trial of Plerixafor for Hematopoietic Stem Cell (HSC) Mobilization in Patients With Sickle Cell Disease
Pilot and Feasibility Trial of Plerixafor for Hematopoietic Stem Cell (HSC) Mobilization in Patients With Sickle Cell Disease
Status: Enrolling
Updated:  1/23/2018
Boston Children's Hospital
mi
from
Boston, MA
Pilot and Feasibility Trial of Plerixafor for Hematopoietic Stem Cell (HSC) Mobilization in Patients With Sickle Cell Disease Pilot and Feasibility Trial of Plerixafor for Hematopoietic Stem Cell (HSC) Mobilization in Patients With Sickle Cell Disease
Pilot and Feasibility Trial of Plerixafor for Hematopoietic Stem Cell (HSC) Mobilization in Patients With Sickle Cell Disease
Status: Enrolling
Updated: 1/23/2018
Boston Children's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Alefacept in Patients With Relapsed/Refractory Aplastic Anemia
A Phase 1/2 Study of Alefacept, a CD2 Receptor Antagonist in Patients With Relapsed/Refractory Aplastic Anemia
Status: Enrolling
Updated:  1/24/2018
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Alefacept in Patients With Relapsed/Refractory Aplastic Anemia
A Phase 1/2 Study of Alefacept, a CD2 Receptor Antagonist in Patients With Relapsed/Refractory Aplastic Anemia
Status: Enrolling
Updated: 1/24/2018
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma
A Single Institution, Open-Label, Nonrandomized Pilot Study of High Dose Epoetin Alfa Administered Once a Week in Patients With Multiple Myeloma: Its Effects on Hemoglobin, Blood Transfusion Requirements and Quality of Life
Status: Enrolling
Updated:  1/24/2018
Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma
A Single Institution, Open-Label, Nonrandomized Pilot Study of High Dose Epoetin Alfa Administered Once a Week in Patients With Multiple Myeloma: Its Effects on Hemoglobin, Blood Transfusion Requirements and Quality of Life
Status: Enrolling
Updated: 1/24/2018
Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Anti-thymocyte Globulin and Cyclosporine as First-Line Therapy in Treating Patients With Severe Aplastic Anemia
Protocol for Prospective Phase II Study of Rabbit Antithymocyte Globulin (r-ATG/Thymoglobulin) and Cyclosporine (CsA) as a First Line Immunosuppressive (IS) Therapy for Severe Aplastic Anemia (sAA)
Status: Enrolling
Updated:  1/25/2018
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Anti-thymocyte Globulin and Cyclosporine as First-Line Therapy in Treating Patients With Severe Aplastic Anemia
Protocol for Prospective Phase II Study of Rabbit Antithymocyte Globulin (r-ATG/Thymoglobulin) and Cyclosporine (CsA) as a First Line Immunosuppressive (IS) Therapy for Severe Aplastic Anemia (sAA)
Status: Enrolling
Updated: 1/25/2018
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Exit Interviews to Assess Impact of Infusion Frequency in Hemophilia A
Exit Interviews to Assess Impact of Infusion Frequency in Hemophilia A
Status: Enrolling
Updated:  1/30/2018
Cleveland
mi
from
Cleveland, OH
Exit Interviews to Assess Impact of Infusion Frequency in Hemophilia A
Exit Interviews to Assess Impact of Infusion Frequency in Hemophilia A
Status: Enrolling
Updated: 1/30/2018
Cleveland
mi
from
Cleveland, OH
Click here to add this to my saved trials
Intravenous Ferric Carboxymaltose vs IV Iron Sucrose or IV Iron Dextran in Treating Iron Deficiency Anemia in Women
A Randomized, Controlled Study to Investigate the Safety and Oxidative Stress Potential of Intravenous Ferric Carboxymaltose (FCM) vs. IV Iron Sucrose or IV Iron Dextran in Treating Iron Deficiency Anemia in Women
Status: Enrolling
Updated:  2/2/2018
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
Intravenous Ferric Carboxymaltose vs IV Iron Sucrose or IV Iron Dextran in Treating Iron Deficiency Anemia in Women
A Randomized, Controlled Study to Investigate the Safety and Oxidative Stress Potential of Intravenous Ferric Carboxymaltose (FCM) vs. IV Iron Sucrose or IV Iron Dextran in Treating Iron Deficiency Anemia in Women
Status: Enrolling
Updated: 2/2/2018
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
Click here to add this to my saved trials
The Feasibility of the PAINReportIt Guided Relaxation Intervention-Outpatient
The Feasibility of the PAINReportIt Guided Relaxation Intervention for Pain and Stress Symptoms in Adult Outpatients With Sickle Cell Disease
Status: Enrolling
Updated:  2/8/2018
University of Florida Hematology Clinic-Medical Plaza
mi
from
Gainesville, FL
The Feasibility of the PAINReportIt Guided Relaxation Intervention-Outpatient
The Feasibility of the PAINReportIt Guided Relaxation Intervention for Pain and Stress Symptoms in Adult Outpatients With Sickle Cell Disease
Status: Enrolling
Updated: 2/8/2018
University of Florida Hematology Clinic-Medical Plaza
mi
from
Gainesville, FL
Click here to add this to my saved trials
Screening Patients With Sickle Cell Disease for Kidney Damage
Screening Patients With Sickle Cell Disease for Kidney Damage
Status: Enrolling
Updated:  2/12/2018
Emory University (Children's Healthcare of Atlanta Pediatric Hospital)
mi
from
Atlanta, GA
Screening Patients With Sickle Cell Disease for Kidney Damage
Screening Patients With Sickle Cell Disease for Kidney Damage
Status: Enrolling
Updated: 2/12/2018
Emory University (Children's Healthcare of Atlanta Pediatric Hospital)
mi
from
Atlanta, GA
Click here to add this to my saved trials
Screening Patients With Sickle Cell Disease for Kidney Damage
Screening Patients With Sickle Cell Disease for Kidney Damage
Status: Enrolling
Updated:  2/12/2018
University of Illinois at Chicago Sickle Cell Center
mi
from
Chicago, IL
Screening Patients With Sickle Cell Disease for Kidney Damage
Screening Patients With Sickle Cell Disease for Kidney Damage
Status: Enrolling
Updated: 2/12/2018
University of Illinois at Chicago Sickle Cell Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Screening Patients With Sickle Cell Disease for Kidney Damage
Screening Patients With Sickle Cell Disease for Kidney Damage
Status: Enrolling
Updated:  2/12/2018
Univeristy of Louisville (Kosair Children's Hospital)
mi
from
Louisville, KY
Screening Patients With Sickle Cell Disease for Kidney Damage
Screening Patients With Sickle Cell Disease for Kidney Damage
Status: Enrolling
Updated: 2/12/2018
Univeristy of Louisville (Kosair Children's Hospital)
mi
from
Louisville, KY
Click here to add this to my saved trials
Screening Patients With Sickle Cell Disease for Kidney Damage
Screening Patients With Sickle Cell Disease for Kidney Damage
Status: Enrolling
Updated:  2/12/2018
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Screening Patients With Sickle Cell Disease for Kidney Damage
Screening Patients With Sickle Cell Disease for Kidney Damage
Status: Enrolling
Updated: 2/12/2018
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Screening Patients With Sickle Cell Disease for Kidney Damage
Screening Patients With Sickle Cell Disease for Kidney Damage
Status: Enrolling
Updated:  2/12/2018
Akron Childen's Hospital
mi
from
Akron, OH
Screening Patients With Sickle Cell Disease for Kidney Damage
Screening Patients With Sickle Cell Disease for Kidney Damage
Status: Enrolling
Updated: 2/12/2018
Akron Childen's Hospital
mi
from
Akron, OH
Click here to add this to my saved trials
Screening Patients With Sickle Cell Disease for Kidney Damage
Screening Patients With Sickle Cell Disease for Kidney Damage
Status: Enrolling
Updated:  2/12/2018
Nationwide Children's Hospital
mi
from
Columbus, OH
Screening Patients With Sickle Cell Disease for Kidney Damage
Screening Patients With Sickle Cell Disease for Kidney Damage
Status: Enrolling
Updated: 2/12/2018
Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Screening Patients With Sickle Cell Disease for Kidney Damage
Screening Patients With Sickle Cell Disease for Kidney Damage
Status: Enrolling
Updated:  2/12/2018
Wayne State University-Children's Hospital of Michigan
mi
from
Detroit, MI
Screening Patients With Sickle Cell Disease for Kidney Damage
Screening Patients With Sickle Cell Disease for Kidney Damage
Status: Enrolling
Updated: 2/12/2018
Wayne State University-Children's Hospital of Michigan
mi
from
Detroit, MI
Click here to add this to my saved trials
Clinical and Laboratory Investigation of Humans With Informative Iron or Erythroid Phenotypes
Clinical and Laboratory Investigation of Humans With Informative Iron or Erythroid Phenotypes
Status: Enrolling
Updated:  2/13/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Clinical and Laboratory Investigation of Humans With Informative Iron or Erythroid Phenotypes
Clinical and Laboratory Investigation of Humans With Informative Iron or Erythroid Phenotypes
Status: Enrolling
Updated: 2/13/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial
Status: Enrolling
Updated:  2/13/2018
University of Colorado
mi
from
Denver, CO
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial
Status: Enrolling
Updated: 2/13/2018
University of Colorado
mi
from
Denver, CO
Click here to add this to my saved trials
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial
Status: Enrolling
Updated:  2/13/2018
Presbyterian - Saint Lukes Medical Center - Health One
mi
from
Denver, CO
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial
Status: Enrolling
Updated: 2/13/2018
Presbyterian - Saint Lukes Medical Center - Health One
mi
from
Denver, CO
Click here to add this to my saved trials
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial
Status: Enrolling
Updated:  2/13/2018
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial
Status: Enrolling
Updated: 2/13/2018
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial
Status: Enrolling
Updated:  2/13/2018
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial
Status: Enrolling
Updated: 2/13/2018
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial
Status: Enrolling
Updated:  2/13/2018
VA Puget Sound Health Care System
mi
from
Seattle, WA
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial
Status: Enrolling
Updated: 2/13/2018
VA Puget Sound Health Care System
mi
from
Seattle, WA
Click here to add this to my saved trials
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial
Status: Enrolling
Updated:  2/13/2018
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial
Status: Enrolling
Updated: 2/13/2018
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial
Status: Enrolling
Updated:  2/13/2018
Aarhus University Hospital
mi
from
Arhus,
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial
Status: Enrolling
Updated: 2/13/2018
Aarhus University Hospital
mi
from
Arhus,
Click here to add this to my saved trials
Evaluation of the AMICUS RBCx System in Sickle Cell Patients
Evaluation of the AMICUS Red Blood Cell Exchange (RBCx) System in Sickle Cell Patients
Status: Enrolling
Updated:  2/20/2018
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Evaluation of the AMICUS RBCx System in Sickle Cell Patients
Evaluation of the AMICUS Red Blood Cell Exchange (RBCx) System in Sickle Cell Patients
Status: Enrolling
Updated: 2/20/2018
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Evaluation of the AMICUS RBCx System in Sickle Cell Patients
Evaluation of the AMICUS Red Blood Cell Exchange (RBCx) System in Sickle Cell Patients
Status: Enrolling
Updated:  2/20/2018
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Evaluation of the AMICUS RBCx System in Sickle Cell Patients
Evaluation of the AMICUS Red Blood Cell Exchange (RBCx) System in Sickle Cell Patients
Status: Enrolling
Updated: 2/20/2018
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Evaluation of the AMICUS RBCx System in Sickle Cell Patients
Evaluation of the AMICUS Red Blood Cell Exchange (RBCx) System in Sickle Cell Patients
Status: Enrolling
Updated:  2/20/2018
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Evaluation of the AMICUS RBCx System in Sickle Cell Patients
Evaluation of the AMICUS Red Blood Cell Exchange (RBCx) System in Sickle Cell Patients
Status: Enrolling
Updated: 2/20/2018
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Evaluation of the AMICUS RBCx System in Sickle Cell Patients
Evaluation of the AMICUS Red Blood Cell Exchange (RBCx) System in Sickle Cell Patients
Status: Enrolling
Updated:  2/20/2018
BloodCenter of Wisconsin
mi
from
Milwaukee, WI
Evaluation of the AMICUS RBCx System in Sickle Cell Patients
Evaluation of the AMICUS Red Blood Cell Exchange (RBCx) System in Sickle Cell Patients
Status: Enrolling
Updated: 2/20/2018
BloodCenter of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Evaluation of the AMICUS RBCx System in Sickle Cell Patients
Evaluation of the AMICUS Red Blood Cell Exchange (RBCx) System in Sickle Cell Patients
Status: Enrolling
Updated:  2/20/2018
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Evaluation of the AMICUS RBCx System in Sickle Cell Patients
Evaluation of the AMICUS Red Blood Cell Exchange (RBCx) System in Sickle Cell Patients
Status: Enrolling
Updated: 2/20/2018
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Evaluation of the AMICUS RBCx System in Sickle Cell Patients
Evaluation of the AMICUS Red Blood Cell Exchange (RBCx) System in Sickle Cell Patients
Status: Enrolling
Updated:  2/20/2018
Washington University
mi
from
Saint Louis, MO
Evaluation of the AMICUS RBCx System in Sickle Cell Patients
Evaluation of the AMICUS Red Blood Cell Exchange (RBCx) System in Sickle Cell Patients
Status: Enrolling
Updated: 2/20/2018
Washington University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Red Blood Cell Transfusion in Patients With Coronary Artery Disease (CAD)
Red Blood Cell Transfusion in Patients With Acute and Chronic Coronary Syndrome
Status: Enrolling
Updated:  2/21/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Red Blood Cell Transfusion in Patients With Coronary Artery Disease (CAD)
Red Blood Cell Transfusion in Patients With Acute and Chronic Coronary Syndrome
Status: Enrolling
Updated: 2/21/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD
A Phase 3 Study of KRX-0502 (Ferric Citrate) for the Treatment of Iron Deficiency Anemia (IDA) in Adult Subjects With Non-Dialysis Dependent (NDD) Chronic Kidney Disease
Status: Enrolling
Updated:  2/22/2018
AKDHC Medical Research Services, LLC
mi
from
Phoenix, AZ
KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD
A Phase 3 Study of KRX-0502 (Ferric Citrate) for the Treatment of Iron Deficiency Anemia (IDA) in Adult Subjects With Non-Dialysis Dependent (NDD) Chronic Kidney Disease
Status: Enrolling
Updated: 2/22/2018
AKDHC Medical Research Services, LLC
mi
from
Phoenix, AZ
Click here to add this to my saved trials
KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD
A Phase 3 Study of KRX-0502 (Ferric Citrate) for the Treatment of Iron Deficiency Anemia (IDA) in Adult Subjects With Non-Dialysis Dependent (NDD) Chronic Kidney Disease
Status: Enrolling
Updated:  2/22/2018
Southwest Kidney Institute
mi
from
Tempe, AZ
KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD
A Phase 3 Study of KRX-0502 (Ferric Citrate) for the Treatment of Iron Deficiency Anemia (IDA) in Adult Subjects With Non-Dialysis Dependent (NDD) Chronic Kidney Disease
Status: Enrolling
Updated: 2/22/2018
Southwest Kidney Institute
mi
from
Tempe, AZ
Click here to add this to my saved trials
KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD
A Phase 3 Study of KRX-0502 (Ferric Citrate) for the Treatment of Iron Deficiency Anemia (IDA) in Adult Subjects With Non-Dialysis Dependent (NDD) Chronic Kidney Disease
Status: Enrolling
Updated:  2/22/2018
California Renal Research
mi
from
Glendale, CA
KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD
A Phase 3 Study of KRX-0502 (Ferric Citrate) for the Treatment of Iron Deficiency Anemia (IDA) in Adult Subjects With Non-Dialysis Dependent (NDD) Chronic Kidney Disease
Status: Enrolling
Updated: 2/22/2018
California Renal Research
mi
from
Glendale, CA
Click here to add this to my saved trials
KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD
A Phase 3 Study of KRX-0502 (Ferric Citrate) for the Treatment of Iron Deficiency Anemia (IDA) in Adult Subjects With Non-Dialysis Dependent (NDD) Chronic Kidney Disease
Status: Enrolling
Updated:  2/22/2018
Southern California Medical Research Center
mi
from
La Palma, CA
KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD
A Phase 3 Study of KRX-0502 (Ferric Citrate) for the Treatment of Iron Deficiency Anemia (IDA) in Adult Subjects With Non-Dialysis Dependent (NDD) Chronic Kidney Disease
Status: Enrolling
Updated: 2/22/2018
Southern California Medical Research Center
mi
from
La Palma, CA
Click here to add this to my saved trials
KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD
A Phase 3 Study of KRX-0502 (Ferric Citrate) for the Treatment of Iron Deficiency Anemia (IDA) in Adult Subjects With Non-Dialysis Dependent (NDD) Chronic Kidney Disease
Status: Enrolling
Updated:  2/22/2018
Academic Medical Research Institute
mi
from
Los Angeles, CA
KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD
A Phase 3 Study of KRX-0502 (Ferric Citrate) for the Treatment of Iron Deficiency Anemia (IDA) in Adult Subjects With Non-Dialysis Dependent (NDD) Chronic Kidney Disease
Status: Enrolling
Updated: 2/22/2018
Academic Medical Research Institute
mi
from
Los Angeles, CA
Click here to add this to my saved trials
KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD
A Phase 3 Study of KRX-0502 (Ferric Citrate) for the Treatment of Iron Deficiency Anemia (IDA) in Adult Subjects With Non-Dialysis Dependent (NDD) Chronic Kidney Disease
Status: Enrolling
Updated:  2/22/2018
Apex Research of Riverside
mi
from
Riverside, CA
KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD
A Phase 3 Study of KRX-0502 (Ferric Citrate) for the Treatment of Iron Deficiency Anemia (IDA) in Adult Subjects With Non-Dialysis Dependent (NDD) Chronic Kidney Disease
Status: Enrolling
Updated: 2/22/2018
Apex Research of Riverside
mi
from
Riverside, CA
Click here to add this to my saved trials
KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD
A Phase 3 Study of KRX-0502 (Ferric Citrate) for the Treatment of Iron Deficiency Anemia (IDA) in Adult Subjects With Non-Dialysis Dependent (NDD) Chronic Kidney Disease
Status: Enrolling
Updated:  2/22/2018
California Institute of Renal Research
mi
from
San Diego, CA
KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD
A Phase 3 Study of KRX-0502 (Ferric Citrate) for the Treatment of Iron Deficiency Anemia (IDA) in Adult Subjects With Non-Dialysis Dependent (NDD) Chronic Kidney Disease
Status: Enrolling
Updated: 2/22/2018
California Institute of Renal Research
mi
from
San Diego, CA
Click here to add this to my saved trials